Camilla Fuchs Andersen
YOU?
Author Swipe
View article: Albuminuria in Type 2 Diabetes and Risk of Cardiorenal Outcomes
Albuminuria in Type 2 Diabetes and Risk of Cardiorenal Outcomes Open
The prevalence of patients with T2D and albuminuria was 40% and may benefit from cardiovascular and renoprotective drugs, whereas 60% with normoalbuminuria still have a high residual risk of cardiovascular disease, warranting increased foc…
View article: Erythrocytosis incidence and thromboembolic risk in heart failure with reduced ejection fraction treated with SGLT2 inhibitors: a nationwide register-based cohort study
Erythrocytosis incidence and thromboembolic risk in heart failure with reduced ejection fraction treated with SGLT2 inhibitors: a nationwide register-based cohort study Open
Although erythrocytosis incidence was higher in SGLT2i-treated HFrEF patients, it was not associated with an increased one-year thromboembolic risk.
View article: Associations of Body Mass Index on worsening of heart failure and mortality in patients with heart failure and reduced left ventricular ejection fraction: A 10-year follow-up study (A NorthStar Substudy)
Associations of Body Mass Index on worsening of heart failure and mortality in patients with heart failure and reduced left ventricular ejection fraction: A 10-year follow-up study (A NorthStar Substudy) Open
Background Obesity is common in heart failure with reduced ejection fraction (HFrEF). As anti-obesity treatments advance, understanding how body mass index (BMI) affects outcomes in HFrEF is increasingly important. Objective To examine whe…
View article: Temporal Trends in Mortality and Hospitalization Risk in Patients With Heart Failure According to the Hospital Frailty Risk Score
Temporal Trends in Mortality and Hospitalization Risk in Patients With Heart Failure According to the Hospital Frailty Risk Score Open
Background Heart failure (HF) and frailty often coexist. However, it is unknown how the interplay between HF and frailty at HF onset impacts prognosis of frail patients with HF and how this has evolved over time. Methods and Results We ide…
View article: The Effect of Empagliflozin on Fluid Volume Status and Cardiac Adipose Tissue in Patients at Risk of Heart Failure: Main Results from the Empire Prevent Metabolic Trial
The Effect of Empagliflozin on Fluid Volume Status and Cardiac Adipose Tissue in Patients at Risk of Heart Failure: Main Results from the Empire Prevent Metabolic Trial Open
View article: Accelerometer-measured physical activity in patients with heart failure and reduced ejection fraction: Determinants and relationship with patient-reported health status
Accelerometer-measured physical activity in patients with heart failure and reduced ejection fraction: Determinants and relationship with patient-reported health status Open
In patients with HFrEF, older age and anemia were independently associated with lower activity. Moreover, physical activity only weakly increased with better health status, suggesting that changes in physical activity reflect improvements …
View article: Excess long-term risk of adverse outcomes in heart failure patients with high and low levels of NT-proBNP: A 7-year follow-up study (NorthStar Trial)
Excess long-term risk of adverse outcomes in heart failure patients with high and low levels of NT-proBNP: A 7-year follow-up study (NorthStar Trial) Open
View article: Impact of breast-, gastrointestinal-, and lung cancer on prognosis in patients with first-time pulmonary embolism: A Danish nationwide cohort study
Impact of breast-, gastrointestinal-, and lung cancer on prognosis in patients with first-time pulmonary embolism: A Danish nationwide cohort study Open
View article: Temporal trends in mortality, heart failure hospitalization, and stroke in heart failure patients with and without atrial fibrillation: A nationwide study from 1997-2018 on 152,059 patients
Temporal trends in mortality, heart failure hospitalization, and stroke in heart failure patients with and without atrial fibrillation: A nationwide study from 1997-2018 on 152,059 patients Open
Background Given the many advances in treating heart failure (HF) and atrial fibrillation (AF) separately over the past decades, it remains unclear how the prognosis of patients diagnosed with both conditions has changed over time. We aime…
View article: Empagliflozin to elderly and obese patients with increased risk of developing heart failure: Study protocol for the Empire Prevent trial program
Empagliflozin to elderly and obese patients with increased risk of developing heart failure: Study protocol for the Empire Prevent trial program Open
View article: Accelerometer-measured physical activity in patients with heart failure and reduced ejection fraction: determinants and relationship with patient-reported health status
Accelerometer-measured physical activity in patients with heart failure and reduced ejection fraction: determinants and relationship with patient-reported health status Open
Background Accelerometer-measured physical activity is an increasingly used endpoint in heart failure (HF) trials. Purpose We aimed to investigate the determinants of accelerometer-measured physical activity and to establish the minimal cl…
View article: The effect of empagliflozin on ketone bodies in patients with heart failure with reduced ejection fraction (Empire HF)
The effect of empagliflozin on ketone bodies in patients with heart failure with reduced ejection fraction (Empire HF) Open
Background The thrifty-substrate hypothesis suggests that Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors increase plasma levels of ketone bodies and create a salutary switch in myocardial fuel metabolism. Purpose We investigated the eff…
View article: The association between the experience of lay responders and response interval to medical emergencies in a rural area: an observational study
The association between the experience of lay responders and response interval to medical emergencies in a rural area: an observational study Open
View article: Reduction of cardiac adipose tissue volume with short‐term empagliflozin treatment in patients with type 2 diabetes: A substudy from the <scp>SIMPLE</scp> randomized clinical trial
Reduction of cardiac adipose tissue volume with short‐term empagliflozin treatment in patients with type 2 diabetes: A substudy from the <span>SIMPLE</span> randomized clinical trial Open
Objective Ectopic accumulation of cardiac adipose tissue volume (CAT) has been associated with cardiac remodelling and cardiac dysfunction in type 2 diabetes and may be a future therapeutic target. In this substudy from the SIMPLE‐trial, w…
View article: Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire <scp>HF</scp> trial
Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire <span>HF</span> trial Open
Aims It remains unknown whether the consistently observed increase in haematocrit with sodium–glucose cotransporter 2 inhibitors is caused by diuresis‐associated haemoconcentration or increased erythropoiesis. We aimed to investigate the e…
View article: Prognosis of acute coronary syndrome stratified by cancer type and status - a nationwide cohort study
Prognosis of acute coronary syndrome stratified by cancer type and status - a nationwide cohort study Open
Active- and non-active cancers were associated with an increased 1-year all-cause mortality compared with patients with history of cancer and no cancer. Cardiovascular disease was the leading cause of death; notably CAG was less frequently…
View article: ODP154 Reduction of Cardiac Adipose Tissue Volume with Short-Term Empagliflozin in Patients with Type 2 Diabetes: Results from the SIMPLE Randomized Clinical Trial
ODP154 Reduction of Cardiac Adipose Tissue Volume with Short-Term Empagliflozin in Patients with Type 2 Diabetes: Results from the SIMPLE Randomized Clinical Trial Open
Background Sodium-glucose transporter 2 inhibitors (SGLT2-is) appear to have rapid clinical cardiovascular benefits in type 2 diabetes. Furthermore, SGLT2-is have known effects on fat metabolism. Cardiac adipose tissue (CAT) correlates wit…
View article: Prognosis following acute coronary syndrome according to cancer type and status – a nationwide Danish cohort study
Prognosis following acute coronary syndrome according to cancer type and status – a nationwide Danish cohort study Open
Background Survival of patients with cardiovascular disease and cancers has increased due to improved treatments. However, the prognosis of acute coronary syndrome (ACS) in cancer patients is widely unknown, challenging clinical decision-m…
View article: The effect of empagliflozin on contractile reserve in heart failure: Prespecified sub-study of a randomized, double-blind, and placebo-controlled trial
The effect of empagliflozin on contractile reserve in heart failure: Prespecified sub-study of a randomized, double-blind, and placebo-controlled trial Open
Empagliflozin for 12 weeks added to guideline-directed HF therapy did not improve LV contractile reserve in patients with HF and reduced ejection fraction.
View article: The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker)
The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker) Open
View article: External validation of a high-sensitive troponin I algorithm for rapid evaluation of acute myocardial infarction in a Danish cohort
External validation of a high-sensitive troponin I algorithm for rapid evaluation of acute myocardial infarction in a Danish cohort Open
Aims An accelerated diagnostic algorithm for ruling-in or ruling-out myocardial infarction (MI) after 1 hour (1 h) has recently been derived and internally validated for the Siemens ADVIA Centaur TNIH assay. We aimed to validate the diagno…
View article: Basic life support skills can be improved among certified basic life support instructors
Basic life support skills can be improved among certified basic life support instructors Open